# ERIS (ERIS) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/eris

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹1,316
- Change: +0.40%
- As of: 2026-09-18
- 1D return: +0.81%
- 5D return: -2.60%
- 1M return: -0.35%
- Latest complete quarter: fy27_q1

## Faxioms Analysis

_As of 2026-09-18_

### Technical Outlook

As of September 18, 2026, ERIS is trading below key moving averages on the daily and weekly charts, indicating a bearish short-to-medium term technical stance, despite a bullish signal on the monthly Supertrend. The daily chart shows the price below the 20-day EMA (1327.18) and 50-day EMA (1351.68), with the Supertrend also in a bearish direction at 1388.18. This aligns with the weekly timeframe, where the price is below its 20-day EMA (1372.46) and 50-day EMA (1414.53), and the weekly Supertrend is bearish at 1550.11. However, the monthly Supertrend is bullish at 751.99, suggesting a potential longer-term positive underpinning that is not currently reflected in shorter timeframes. Recent anomalies include a moderate upward move with high participation on September 18, 2026, and an extreme downward move on September 15, 2026. The stock is currently trading near its nearest support level of ₹1317.1, which is approximately 0.32% below the current price. The nearest resistance is observed at ₹1329.09, about 0.59% above the current price. The stock's current drawdown stands at -0.28%, with an annualized volatility of 33%.

- Daily and weekly timeframes show a bearish trend, with prices below key EMAs and Supertrend.
- Monthly Supertrend indicates a bullish signal at 751.99, contrasting with shorter timeframes.
- Nearest support is at ₹1317.1 (0.32% below current price), nearest resistance is at ₹1329.09 (0.59% above current price).
- Watch for a sustained break above the ₹1329.09 resistance level to challenge the bearish short-term outlook.
- A move below the ₹1317.1 support could reinforce the bearish sentiment.

- Harami
- Bearish Engulfing Reversal
- Evening Star
- Morning Star
- Doji

### What Changed

Eris Lifesciences (ERIS) on the NSE has seen a slight increase in its stock price, moving from ₹1310.7 to ₹1321.3 between two recent observation dates. The company's profile and the exchange it is listed on remain unchanged. There are no new filings or news items reported in the provided evidence, indicating that the recent price movement is the primary observable development.

- Eris Lifesciences (ERIS) stock price increased from ₹1310.7 to ₹1321.3.
- The observation date for the latest price was 2026-09-18.
- The company continues to be listed on the NSE.
- No new filings or news were reported as of 2026-09-18.

### Official Filings

Eris Lifesciences Limited has disclosed a change in its senior leadership with the resignation of Mr. Krishnakumar Vaidyanathan as Executive Director and Chief Operating Officer (COO), effective September 30, 2026. This departure is noted as a move to pursue external professional opportunities. In parallel, the company has secured a new term loan facility of ₹45 crore from Axis Bank Limited, drawn on September 9, 2026, to address other liabilities. This loan is secured by a charge on the company's brands, and following this drawdown, the total outstanding loan balance has increased to ₹210.77 crore. The company has indicated this is a routine financial adjustment that will not impact the expected net debt for the quarter. Shareholders will also convene for the Annual General Meeting (AGM) on September 25, 2026, to approve financial statements for the fiscal year ended March 31, 2026, and to vote on director re-appointments and cost auditor remuneration.

- Mr. Krishnakumar Vaidyanathan resigned as Executive Director & COO, effective September 30, 2026.
- Eris Lifesciences Limited entered into a term loan agreement with Axis Bank Limited for ₹45 crore, drawn on September 9, 2026.
- The new loan is secured by a charge on the company's brands.
- Total outstanding loan balance increased to ₹210.77 crore following the drawdown.
- The company's 20th Annual General Meeting is scheduled for September 25, 2026, to approve FY26 financial statements and other corporate actions.

- Eris Lifesciences Limited has informed the Exchange regarding Resignation of Mr Krishnakumar Vaidyanathan as Executive Director of the company w.e.f. September 30, 2026. |SUBJECT: Resignation
- Eris Lifesciences Limited has informed the Exchange about Change in Directors/KMP/SMP/Auditor/RTA |SUBJECT: Change in Directors/KMP/SMP/Auditor/RTA
- Eris Lifesciences Limited has informed the Exchange about Loan Agreement |SUBJECT: Agreements
- Eris Lifesciences Limited has informed the Exchange about Agreements (Sub-para 5-Para B) |SUBJECT: Agreements (Sub-para 5-Para B)
- Eris Lifesciences Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- Eris Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication
- Eris Lifesciences Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 25, 2026 |SUBJECT: Shareholders meeting
- Eris Lifesciences Limited has informed the Exchange about Notice of Shareholders Meeting for Annual General Meeting to be held on 25-Sep-2026 |SUBJECT: Notice Of Shareholders Meetings-XBRL
- AS ON DATE : 02-SEP-26

### Fundamentals

Eris Lifesciences reported revenue from operations of ₹873.25 crore for Q1 FY2026-27. This represents an increase from the ₹807.45 crore reported in Q3 FY2025-26 and ₹756.56 crore in Q4 FY2025-26. Profit Before Tax (PBT) for Q1 FY2026-27 stood at ₹179.89 crore, showing an increase from ₹160.61 crore in Q4 FY2025-26 and ₹145.23 crore in Q3 FY2025-26. The company's tax expense was ₹36.17 crore in Q1 FY2026-27, compared to a negative tax expense of -₹119.69 crore in Q4 FY2025-26 and ₹36.52 crore in Q3 FY2025-26. Finance costs remained relatively stable, reported at ₹46.65 crore in Q1 FY2026-27, ₹45.62 crore in Q4 FY2025-26, and ₹48.82 crore in Q3 FY2025-26. Other expenses saw an increase to ₹184.36 crore in Q1 FY2026-27 from ₹160.89 crore in Q4 FY2025-26 and ₹164.46 crore in Q3 FY2025-26. Profit Before Exceptional Items And Tax followed a similar upward trend, reaching ₹179.89 crore in Q1 FY2026-27 from ₹160.61 crore in Q4 FY2025-26 and ₹162.47 crore in Q3 FY2025-26.

- Revenue from operations for Q1 FY2026-27 was ₹873.25 crore.
- Profit Before Tax (PBT) for Q1 FY2026-27 was ₹179.89 crore.
- Tax expense for Q1 FY2026-27 was ₹36.17 crore.
- Finance costs for Q1 FY2026-27 were ₹46.65 crore.
- Other expenses for Q1 FY2026-27 were ₹184.36 crore.

### Bull Case

The company's monthly technical trend indicates a bullish setup, with the Supertrend indicator at 751.99 and a bullish direction observed as of September 18, 2026. This is supported by a positive monthly Average Directional Index (ADX) of 24.05, suggesting a trending market on a longer timeframe. However, daily and weekly trends are currently showing a bearish Supertrend direction, indicating potential short-term headwinds.

- Monthly Supertrend indicator is 751.99 with a bullish direction as of September 18, 2026.
- Monthly ADX is 24.05, suggesting a trending market on a monthly basis.
- Daily Supertrend direction is bearish as of September 18, 2026.
- Weekly Supertrend direction is bearish as of September 18, 2026.

- Domestic pharma market sustains growth momentum, but margins remain key

### Bear Case

The company's stock is exhibiting signs of technical weakness across multiple timeframes. Daily and weekly trends are classified as bearish, with the Supertrend indicator suggesting downward momentum. Price action is currently below key moving averages, including the 20-day, 50-day, and 200-day Simple Moving Averages (SMA) and Exponential Moving Averages (EMA). The stock has also experienced a significant drawdown of -28%, with a maximum drawdown of -31% observed. While the monthly trend shows a bullish Supertrend direction, the daily and weekly indicators point to prevailing caution.

- The daily Supertrend direction is bearish as of 2026-09-18.
- The weekly Supertrend direction is bearish as of 2026-09-18.
- The stock's current drawdown is -28%, with a maximum drawdown of -31%.
- The closing price of ₹1321.3 on 2026-09-18 is below the 20-day SMA of ₹1317.68 and the 50-day SMA of ₹1367.13.

- Domestic pharma market sustains growth momentum, but margins remain key

### FAQs

**What is the company's current financial position regarding its debt?**

As of September 9, 2026, Eris Lifesciences Limited entered into a term loan agreement with Axis Bank Limited for ₹45 crore to meet other liabilities. This drawdown brings the total outstanding loan balance to ₹210.77 crore. The company stated this is a routine financial adjustment and will not impact the expected net debt for the quarter.

**What recent changes have occurred in the company's key management?**

Mr. Krishnakumar Vaidyanathan resigned as Executive Director and Chief Operating Officer (COO) of Eris Lifesciences Limited, effective September 30, 2026. This resignation was accepted by the Chairman, and the cessation event was disclosed on September 11, 2026.

**How has Eris Lifesciences performed over different time periods?**

As of September 18, 2026, Eris Lifesciences has shown the following returns: a 1% return in the last day, a 1% return over the last 10 days, a -2% return over the last month, a -8% return over the last three months, and a 1% return over the last six months. Over the past year, the stock has returned -19%, and year-to-date, it has returned -12%.

**What are the key technical indicators for Eris Lifesciences as of September 18, 2026?**

On a daily basis, the stock's closing price was ₹1321.3, with the 20-day Exponential Moving Average (EMA) at ₹1327.18 and the 50-day EMA at ₹1351.68. The Supertrend indicator is showing a bearish direction at ₹1388.18. On a monthly basis, the Supertrend is bullish at ₹751.99, with the 20-day EMA at ₹1395.66. The weekly trend shows a bearish Supertrend at ₹1550.11 and a 20-day EMA of ₹1372.46.

- Domestic pharma market sustains growth momentum, but margins remain key
- Eris Lifesciences Limited has informed the Exchange regarding Resignation of Mr Krishnakumar Vaidyanathan as Executive Director of the company w.e.f. September 30, 2026. |SUBJECT: Resignation
- Eris Lifesciences Limited has informed the Exchange about Change in Directors/KMP/SMP/Auditor/RTA |SUBJECT: Change in Directors/KMP/SMP/Auditor/RTA
- Eris Lifesciences Limited has informed the Exchange about Loan Agreement |SUBJECT: Agreements
- Eris Lifesciences Limited has informed the Exchange about Agreements (Sub-para 5-Para B) |SUBJECT: Agreements (Sub-para 5-Para B)
## Technical analytics

- As of: 2026-09-18
- Daily trend: Weak Uptrend
- Weekly trend: Weak Downtrend
- Pivot point: ₹1,317.1
- Risk regime: Price Risk Requires Attention

### Support levels
- 1264.0625
- 1228.56875
- 1200

### Resistance levels
- 1329.0948486328125
- 1417.375
- 1448.653125

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | +0.81% |
| return_10 | +1.37% |
| return_1m | -2.13% |
| return_1y | -19.24% |
| return_20 | -0.35% |
| return_3m | -7.64% |
| return_5 | -2.60% |
| return_6m | +1.01% |
| return_since_start | -0.75% |
| return_ytd | -12.00% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | elevated_risk |
| label | Price risk requires attention |
| summary | Recent drawdown or price variability is high enough to warrant closer monitoring. |
| maximum_drawdown | -31.21% |
| annualized_volatility | +32.80% |

## Quarterly financials

- Latest complete quarter: fy27_q1

# Revenue Jumps and Margins Remain Stable

Eris Lifesciences Limited reported a sharp increase in revenue for the quarter ended 30 June 2026 (Q1 FY2026-27). Revenue from operations rose to ₹873.25 crore, marking the highest quarterly top line in the five quarters shown. Profit before tax grew in line with revenue, while net profit rose 14.56% as tax expenses normalised. Profitability margins were largely unchanged from a year ago.

## Revenue Growth

Revenue from operations was ₹873.25 crore, up 12.97% from ₹773 crore in Q1 FY2025-26 and 15.42% higher than ₹756.56 crore in the immediately preceding quarter (Q4 FY2025-26). The sequential increase reversed a 6.3% quarter-on-quarter decline in Q4 FY2025-26 and represents the highest quarterly revenue among the five periods provided.

## Profitability

Profit before tax (PBT) came in at ₹179.89 crore, a 12.28% rise from ₹160.21 crore a year ago. The PBT margin was 20.6% of revenue, essentially unchanged from 20.7% in the year-ago quarter. Net profit after tax increased to ₹143.32 crore, up 14.56% from ₹125.10 crore in Q1 FY2025-26. The net profit margin moved from 16.2% to 16.4%. The sequential comparison with Q4 FY2025-26 is distorted by an unusual negative tax expense of ₹119.69 crore in that period, which had inflated net profit to ₹279.10 crore. The current quarter’s tax expense of ₹36.17 crore returned to a level consistent with the company’s typical quarterly tax outlays.

## Expense Structure

Total expenses (excluding other income) were ₹695.75 crore. Key components included:

- Combined cost of materials consumed, purchases of stock-in-trade, and changes in inventories: ₹239.25 crore (27.4% of revenue).
- Employee benefit expense: ₹153.42 crore (17.6% of revenue).
- Other expenses: ₹184.36 crore, up 10.25% from ₹167.22 crore a year ago. As a percentage of revenue, these costs edged down from 21.6% to 21.1%, reflecting revenue growth that outpaced the increase in selling, marketing, and related expenses.
- Finance costs: ₹46.65 crore, down 4.17% from ₹48.68 crore a year earlier but slightly above the ₹45.62 crore incurred in the preceding quarter.
- Depreciation and amortisation expense: ₹72.07 crore.

## Earnings Per Share

Basic earnings per share from continuing operations was ₹10.28, compared to ₹8.66 in Q1 FY2025-26 (an increase of 18.71%). Diluted earnings per share rose from ₹8.64 to ₹10.26 over the same period.

## Key Takeaway

The quarter delivered a significant increase in revenue, with the top line reaching its highest level in the five periods shown. Profit before tax grew at a similar pace, and margins remained broadly stable. The 15.4% sequential rebound after a 6.3% decline the prior quarter was notable. Finance costs declined year-on-year but ticked up from the immediate prior quarter. Overall, the results show a strong start to the fiscal year, with both revenue and profitability moving higher while cost ratios held steady.

### Ratios

## Official filings

- 2026-09-11 — Management Change: Eris Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ERIS_11092026160851_Intimationsigned.pdf)
- 2026-09-11 — Generic Announcement: Eris Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CIM_15266_WebXMLFile_20260911_161142004.xml)
- 2026-09-11 — Generic Announcement: Eris Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CIM_15266_WebXMLFile_20260911_161032953.xml)
- 2026-09-09 — Generic Announcement: Eris Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ERIS_09092026170436_intimationsigned.pdf)
- 2026-09-09 — Generic Announcement: Eris Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/REG30_PARA_B_15266_WebXMLFile_20260909_174113895.xml)
- 2026-09-07 — Generic Announcement: Eris Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ERIS_07092026121513_Intimationsigned.pdf)
- 2026-09-02 — Generic Announcement: Eris Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ERIS_02092026192315_Intimationsigned.pdf)
- 2026-09-02 — Generic Announcement: Eris Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ERIS_02092026190541_Intimationsigned.pdf)
- 2026-09-02 — Generic Announcement: Eris Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/NOTICE_OF_SHAREHOLDERS_MEETINGS_15266_WebXMLFile_20260902_185913428.xml)
- 2026-09-01 — Annual Report: Eris Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/annual_reports/AR_31142_ERIS_2025_2026_A_18207532_02092026185621.pdf)
- 2026-08-31 — Generic Announcement: Eris Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ERIS_31082026111919_Intimationsigned.pdf)
- 2026-08-24 — Generic Announcement: Eris Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_15266_WebXMLFile_20260824_155627905.xml)
- 2026-08-24 — Generic Announcement: Eris Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ERIS_24082026155310_Intimationsigned.pdf)
- 2026-08-12 — Generic Announcement: Eris Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_15266_WebXMLFile_20260812_153444555.xml)
- 2026-08-12 — Generic Announcement: Eris Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ERIS_12082026153958_Intimationsigned.pdf)
- 2026-08-06 — Generic Announcement: Eris Lifesciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/REG30_PARA_B_15266_WebXMLFile_20260806_094116843.xml)
- 2026-08-06 — Generic Announcement: Eris Lifesciences Limited has drawn down a working capital term loan of ₹64,40,00,000 from Axis Bank Limited on August 5, 2026, to meet short-term liabilities. The loan agreement, executed on August 5, 2026, involves Axis Bank having a second charge on assets already created for existing working capital facilities. The company stated that its aggregate debt level would remain unchanged. — [Official attachment](https://nsearchives.nseindia.com/corporate/ERIS_06082026094406_Signedintimation.pdf)
- 2026-08-04 — Generic Announcement: Eris Lifesciences Limited has made available the transcript of its analyst and investor call held after announcing financial results for the quarter ended June 30, 2026. The transcript is accessible on the company's website. — [Official attachment](https://nsearchives.nseindia.com/corporate/ERIS_04082026103026_intimationsigned.pdf)
- 2026-07-30 — Generic Announcement: Eris Lifesciences Limited allotted 4,816 equity shares on July 30, 2026, under its ESOP-2017 Scheme at a premium of Rs. 450.04 per share. This allotment increased the company's paid-up share capital to Rs. 13,85,83,305/- comprising 13,85,83,305 equity shares. — [Official attachment](https://nsearchives.nseindia.com/corporate/ERIS_30072026145739_intimationsigned.pdf)
- 2026-07-30 — Generic Announcement: Eris Lifesciences Limited management will participate in a virtual investor conference with Bandhan Mutual Fund on August 4, 2026, at 4:00 PM IST. The company will refer to publicly available documents and will not discuss unpublished price sensitive information. This schedule is subject to change due to unforeseen developments. — [Official attachment](https://nsearchives.nseindia.com/corporate/ERIS_30072026151631_Intimationsigned.pdf)
- 2026-07-29 — Earnings Presentation: Eris Lifesciences Limited reported Q1 FY27 financial results with consolidated revenue of ₹873 crore, a 13% year-over-year increase, and consolidated Profit After Tax (PAT) of ₹143 crore, up 14.5% year-over-year. The Domestic Branded Formulations (DBF) segment revenue grew 14.2% year-over-year to ₹801 crore, with 7 out of 10 therapies showing double-digit growth. The company's international business, Swiss Parenterals, reported Q1 revenue of ₹72 crore, with EU CAPA actions underway and sites targeted to be audit-ready by December 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/ERIS_29072026131516_intimationsigned.pdf)
- 2026-07-29 — Generic Announcement: Eris Lifesciences Limited has made available the recording of its earnings conference call for the quarter ended June 30, 2026. The call, held on July 29, 2026, discussed the company's unaudited consolidated and standalone financial results. The recording can be accessed on the company's website via a provided link. — [Official attachment](https://nsearchives.nseindia.com/corporate/ERIS_29072026183117_intimationsigned.pdf)
- 2026-07-29 — Generic Announcement: Eris Lifesciences Limited's Board of Directors approved unaudited consolidated financial results on July 29, 2026. The company acquired the Branded Probiotics Business from Velbiom Probiotics Private Limited for Rs 50 Crores on March 31, 2026. A deferred tax credit of Rs 150 Crores was recognized due to a revised tax rate, and an increase in gratuity and leave liability of Rs 17.24 Crores resulted from new labor codes. — [Official attachment](https://nsearchives.nseindia.com/corporate/ERIS_29072026130816_Signedoutcome.pdf)
- 2026-07-23 — Official Filing: Eris Lifesciences Limited will host its Q1 FY2027 Earnings Call virtually on July 29, 2026, at 04:30:00. The call will discuss the company's Q1 FY2027 financial results. A registration link for the virtual meeting is provided, and Atul Modi can be contacted for further details.
- 2026-07-23 — Generic Announcement: Eris Lifesciences Limited will hold a conference call for analysts and investors on Wednesday, July 29, 2026, at 04:30 P.M. IST to discuss the standalone and consolidated unaudited financial results for the quarter ended June 30, 2026. This follows a prior intimation regarding the Board of Directors meeting to approve these results. — [Official attachment](https://nsearchives.nseindia.com/corporate/ERIS_23072026143454_Intimationsigned.pdf)

## News and market events

- 2026-09-16 — Mint: **Domestic pharma market sustains growth momentum, but margins remain key** — Domestic pharma growth remained strong in August, led by price hikes and new launches, but weak volumes and US tariff uncertainty mean a sustained margin recovery will be crucial for sector performance. — [Source](https://www.livemint.com/market/mark-to-market/indian-pharma-market-ipm-pharma-stocks-domestic-pharma-dr-reddy-s-laboratories-sun-pharma-ajanta-pharma-glenmark-11789538290089.html)
- 2026-09-11 — MONEYCONTROL: **Eris Lifesciences COO V Krishnakumar steps down, set to join Biological E** — V Krishnakumar, Eris Lifesciences, Biological E, BE BioSol, Eris Lifesciences COO, Biological E CEO, CDMO business, biopharma, vaccine manufacturers, pharma leadership, Krishnakumar resignation, Eris Lifesciences resignation — [Source](https://www.moneycontrol.com/news/business/eris-lifesciences-coo-v-krishnakumar-steps-down-set-to-join-biological-e-14028078.html)
- 2026-09-08 — Economic Times: **Tata Capital Healthcare Fund to exit Linux Laboratories as ChrysCapital buys 20-25% stake** — Private equity firm ChrysCapital is set to acquire a significant stake in Linux Laboratories. This deal will see existing investor Tata Capital Healthcare Fund exit its entire holding. Linux Laboratories focuses on central nervous system therapies and has a strong brand portfolio. The company anticipates robust revenue and Ebitda growth in the coming years. This acquisition highlights continued private equity interest in India's pharmaceutical sector. — [Source](https://economictimes.indiatimes.com/news/company/corporate-trends/tata-capital-healthcare-fund-to-exit-linux-laboratories-as-chryscapital-buys-20-25-stake/articleshow/133939441.cms)
- 2026-08-06 — The Hindu: **Sensex today | Stock Market Live: Sensex rises 250 pts, Nifty holds 24,600 on US-Iran peace hopes, RBI outlook; Neuland Lab shares up 9.6%** — Sensex, Nifty, Share Prices LIVE: Sensex was up 160.95 pts or 0.20% to 78,741.95 at 9.16 am after opening at 78,782.43 from the previous close of 78,581; Nifty inched up 8.70 pts or 0.04% to 24,633.35. — [Source](https://www.thehindubusinessline.com/markets/sensex-nifty50-today-stock-market-live-updates-6-august-2026/article71309748.ece)
- 2026-07-29 — CNBC-TV18: **Eris Lifesciences' Q1 profit jumps 21%, but margins come under pressure** — The drugmaker reported double-digit growth in revenue and profit for the June quarter, even as rising costs squeezed operating margins. — [Source](https://www.cnbctv18.com/market/eris-lifesciences-q1-pat-up-21-pc-shares-gain-2-pc-after-results-19956646.htm)
- 2026-07-29 — CNBC-TV18: **Sensex Today | Stock Market LIVE Updates: Nifty surges 260 points; Kaynes Tech up 12%** — Sensex Today | Stock Market LIVE Updates: We are the halfway mark of the day's trade, and the bulls look in a strong position. The markets are on the rise, and are trading on a strong footing. The Nifty up over 240 points, jumping to 24,200. The Nifty Bank index is up 400 points, rising to 57,000. Infosys, Larsen & Toubro and HUL are the top gainers. — [Source](https://www.cnbctv18.com/market/stock-market-live-updates-sensex-nifty-50-today-hul-asian-paints-adani-oil-lt-grse-it-dmart-share-price-liveblog-19956206.htm)

## Business profile

**Strategic vision:** Pharmaceutical company developing and marketing branded formulations for chronic diseases.

### Business segments
- **Cardio-Metabolic:** Focuses on addressing chronic and sub-chronic diseases, with a core presence in the cardio-metabolic therapeutic area.
- **Anti-Diabetes:** Includes oral anti-diabetic medications and insulin products.
- **Cardiovascular Care:** Products aimed at managing cardiovascular health.
- **Vitamins, Minerals, and Nutrition (VMN):** Nutritional supplements and products.
- **Emerging Therapeutic Areas:** Expanding into dermatology, gynaecology, neuroscience, nephrology, oncology, and critical care.
- **Injectables:** Segment includes sterile injectables, acquired through Swiss Parenterals, and branded injectables in critical care.
- **Oncology:** Entry into the oncology segment with a portfolio of monoclonal antibodies.

### Competitive strengths
- Vertically integrated pharmaceutical operations with WHO-GMP approved manufacturing facilities.
- Extensive distribution network across India.
- Strategic acquisitions to expand into new therapeutic areas and product segments.

## Related stocks

- [ABBOTINDIA (Healthcare)](https://faxioms.com/stocks/abbotindia) — +5.50%
- [ACUTAAS (Healthcare)](https://faxioms.com/stocks/acutaas) — +3.86%
- [AJANTPHARM (Healthcare)](https://faxioms.com/stocks/ajantpharm) — +1.61%
- [ALKEM (Healthcare)](https://faxioms.com/stocks/alkem) — +0.14%
- [ANTHEM (Healthcare)](https://faxioms.com/stocks/anthem) — -0.35%

## Freshness and sources

- Data as of: 2026-09-18
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/eris
Markdown representation: https://faxioms.com/stocks/eris?render=md